Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... SAN DIEGO, April 9, 2012 ADVENTRX Pharmaceuticals, Inc. ... establishment of a Regulatory Advisory Board (RAB). The RAB ... Company management in its interactions with the U.S. Food ... JD, who is rendering legal advice to Company management, ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
... 2012  Albright Stonebridge Group (ASG), a global strategy ... senior advisors – Hakan Akbas, Steven Bipes, Brian ... leading ASG,s commercial activities and advising clients on ... clients of ASG,s Brazil practice as they look ...
Cached Biology Technology:ADVENTRX Announces Establishment of Regulatory Advisory Board 2ADVENTRX Announces Establishment of Regulatory Advisory Board 3ADVENTRX Announces Establishment of Regulatory Advisory Board 4ADVENTRX Announces Establishment of Regulatory Advisory Board 5ADVENTRX Announces Establishment of Regulatory Advisory Board 6UK company to demonstrate their commercially effective graphene production process 2Experts Strengthen Albright Stonebridge Group's Global Reach 2Experts Strengthen Albright Stonebridge Group's Global Reach 3
(Date:4/17/2014)... recent Yokahama IPCC meeting painted a stark warning on ... which has a greenhouse effect 32 times that of ... shown that humic substances act as fully regenerable electron ... are held in wetlands instead of being released to ... system is disrupted it may enter into a vicious ...
(Date:4/17/2014)... the genetic information of DNA is used to ... numerous different functions in living organisms. Messenger RNA ... expression, by relating the genetic information of DNA ... , By examining the different types and ... at a given time, researchers can determine which ...
(Date:4/17/2014)... uncovered a new way the immune system may fight ... to use immune cells to treat illness. , The ... immunological equivalent of "neighborhood police" specialized squads of ... instead of an entire city, the body. , Scientists ... have shown that the liver, skin and uterus each ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2
... presented the 2013 Gustav O. Lienhard Award to Steven ... have helped save millions from premature, smoking-related deaths. ... as well as his work to improve end-of-life care. ... award to a dedicated champion of health for Americans ...
... -- Carnegie Mellon University President Subra Suresh has been ... making him the only current university president to be ... National Academy is among the highest professional distinctions accorded ... membership honors those who have made outstanding contributions to ...
... WASHINGTON -- The Institute of Medicine of the National Academies ... Clayton for their outstanding service today at the IOM,s 43rd ... Medal, awarded to an IOM member for distinguished service over ... on the Quality of Health Care in America, which produced ...
Cached Biology News:Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 2Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 3Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 4Carnegie Mellon President Subra Suresh elected to Institute of Medicine 2Institute of Medicine honors members for outstanding service 2Institute of Medicine honors members for outstanding service 3
... Development, Pharmaceutical Development, Physician Owned Labs, Drugs of Abuse, and Industrial Testing applications. Analyzer ... ... ... ...
... OS X provides the most highly integrated ... analysis and molecular biology data management available ... Suite you can store manage view analyze ... molecular biology data all within one integrated ...
... determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, ... ... ... ...
rat Leptin...
Biology Products: